Transurethral plasmakinetic resection of prostate in high-risk benign prostatic hyperplasia patients:a multicenter prospective study
LI Fei
GENG Jie
CHEN Hongbo
ZHOU Zhijun
LIU Xiaohua
SHI Hongbo
DU Dan
ZHU Tao
ZHANG Jingyu
LI Xiaodong
QUE Hui
SONG Hongfei
YAO Qisheng
DOU Zhongling
RUAN Jianzhong
ZHENG Jiang
ZHU Ziqing
REN Xuanyi
HUANG Qiao
GONG Kan
LIU Tongzu
HE Dalin
ZENG Xiantao
Abstract：Objective To investigate the clinical efficacy of transurethral plasmakinetic resection of prostate(TUPKP)in treating high-risk benign prostatic hyperplasia(BPH)patients.Methods A prospective multicenter study design was employed.Patients with high-risk BPH treated with TUPKP were enrolled in the urology departments of 20 hospitals nationwide according to the inclusion and exclusion criteria.Relevant data regarding patient baseline,perioperative period,and 3-month postoperative follow-up were analyzed to evaluate efficacy and safety.Results From September 2016 to December 2018,a total of 229 high-risk BPH patients were enrolled.Compared to baseline at the 3-month follow-up,the change in the International Prostate Symptom Score was-17.28[95％CI(-18.02,-16.54)],the change in maximum urinary flow rate was 5.61[95％CI(0.68,10.54)]mL·s-1,the change in residual urine volume was-84.50[95％CI(-96.49,-72.51)]mL,and the change in quality of life score was-3.24[95％CI(-3.42,-3.06)],all showing significant differences(P＜0.05).The incidence of intraoperative and postoperative complications was low,and no surgery-related adverse events occurred.Conclusion TUPKP can be used to treat high-risk BPH patients,and it is recommended to be performed by skilled surgeons.
Keywords：Transurethral plasmakinetic resection of prostateBenign prostatic hyperplasiaHigh-risk patientsCardiovascular diseases
Publication Date：2024-04-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：10( 381-390 )